NIKA PHARMACEUTICALS, INC

OTC:NIKA

Pharmaceutical Preparations·HENDERSON, NV

CEO

Savov Dimitar Slavchev

Summary Financials

Revenue

FY 2024

Adj. EBITDA

—

Net Income

-$64,833

FY 2024

EPS (Diluted)

$0.00

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$19,596

FY 2024

Total Debt

$18,180

FY 2023

Net Cash

$1,416

FY 2023

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—

Revenue

FY 2024

Adj. EBITDA

—

Net Income

-$64,833

FY 2024

EPS (Diluted)

$0.00

FY 2024

Stock Price

—

52W Range

—

P/E Ratio

—

Market Cap

—

Cash

$19,596

FY 2024

Total Debt

$18,180

FY 2023

Net Cash

$1,416

FY 2023

Enterprise Value

—

Debt / EBITDA

—

EV / EBITDA

—

Employees

—